Cargando…

It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent

It has been shown that triple antiplatelet therapy with cilostazol results in better clinical outcomes than dual therapy in patients treated with a first-generation drug-eluting stent (DES); however, it is unclear whether triple antiplatelet therapy has a similar efficacy after the implantation of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ju-Youn, Choi, Yun-Seok, Kwon, Ami, Chung, Woo-Baek, Park, Chul-Soo, Kim, Hee-Yeol, Chang, Kiyuk, Lee, Man-Young, Chung, Wook-Sung, Seung, Ki-Bae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652826/ https://www.ncbi.nlm.nih.gov/pubmed/26579817 http://dx.doi.org/10.1097/MD.0000000000002062

Ejemplares similares

Gender differences of in-hospital outcomes in patients undergoing percutaneous coronary intervention in the drug-eluting stent era
por: Kim, Hack-Lyoung, et al.
Publicado: (2019)

Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug‐Eluting Stents in East Asian Patients: Results From the PTRG‐DES (Platelet Function and Genotype‐Related Long‐Term Prognosis in Drug‐Eluting Stent–Treated Patients With Coronary Artery Disease) Consortium
por: Kim, Soo‐Jin, et al.
Publicado: (2023)

Are Drug Eluting Stents Worth Triple Therapy?
por: Heidenreich, Paul
Publicado: (2017)

Predictive value of neutrophil-to-lymphocyte ratio on drug eluting stent restenosis in patients with type 2 diabetes mellitus
por: Wang, Zhi-Chao, et al.
Publicado: (2020)

The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation
por: Jeon, Doo-Soo, et al.
Publicado: (2010)

Efficacy of Triple Anti-Platelet Therapy Including Cilostazol in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stent Implantation
por: Park, Keun-Ho, et al.
Publicado: (2009)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Stent Optimization Using Adjunctive Balloon Dilatation in the Era of Second-Generation Drug-Eluting Stents
por: Kim, Min Chul, et al.
Publicado: (2017)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
por: Whitbeck, Matthew G., et al.
Publicado: (2013)

Two Cases of Percutaneous Intervention for Coronary Artery Bypass Graft Anastomoses With Paclitaxel-Eluting Balloon Catheters
por: Uhm, Jae-Sun, et al.
Publicado: (2011)

Five-year major clinical outcomes between first-generation and second-generation drug-eluting stents in acute myocardial infarction patients underwent percutaneous coronary intervention
por: Kim, Yong Hoon, et al.
Publicado: (2018)

One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2016)

Bifurcation strategies using second-generation drug-eluting stents on clinical outcomes in diabetic patients
por: Cha, Jung-Joon, et al.
Publicado: (2022)

Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost–benefit analysis
por: Poder, Thomas G., et al.
Publicado: (2017)

Comparison of Triple Anti-Platelet Therapy (Aspirin, Clopidogrel, and Cilostazol) and Double Anti-Platelet Therapy (Aspirin and Clopidogrel) on Platelet Aggregation in Type 2 Diabetic Patients Undergoing Drug-Eluting Stent Implantation
por: Yang, Tae-Hyun, et al.
Publicado: (2009)

Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation
por: Hong, Sung-Jin, et al.
Publicado: (2019)

Percutaneous insertion of a novel dedicated metal stent to treat malignant hilar biliary obstruction
por: Cortese, Francesco, et al.
Publicado: (2022)

Zotarolimus-eluting stent-induced hypersensitivity pneumonitis
por: Shin, Hong-Won, et al.
Publicado: (2013)

Clinical outcomes of second-generation limus-eluting stents compared to paclitaxel-eluting stents for acute myocardial infarction with cardiogenic shock
por: Mao, Chun-Tai, et al.
Publicado: (2019)

Patterns of Antiplatelet Therapy During Noncardiac Surgery in Patients With Second‐Generation Drug‐Eluting Stents
por: Kim, Choongki, et al.
Publicado: (2020)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
por: Liu, Yen-Wen, et al.
Publicado: (2021)

Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium
por: Jeon, Ki-Hyun, et al.
Publicado: (2023)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice
por: Lee, Joo Myung, et al.
Publicado: (2023)

Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis
por: Zeng, MengYing, et al.
Publicado: (2021)

Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial
por: Lee, Joo Myung, et al.
Publicado: (2013)

Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents
por: Park, Sun-Kyung, et al.
Publicado: (2017)

Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents
por: Lim, Sungmin, et al.
Publicado: (2021)

Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
por: Kim, Do Hyung, et al.
Publicado: (2013)

Long-term outcomes of intravascular ultrasound-guided implantation of bare metal stents versus drug-eluting stents in primary percutaneous coronary intervention
por: Cho, Yun-Kyeong, et al.
Publicado: (2014)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Comparisons of the Effects of Stent Eccentricity on the Neointimal Hyperplasia between Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent
por: Kim, Byeong-Keuk, et al.
Publicado: (2010)

Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer
por: Yang, Hyoung-Mo, et al.
Publicado: (2017)

Three‐year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus‐eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus‐eluting stent: A randomized controlled trial
por: Kim, Soo‐Hyun, et al.
Publicado: (2019)

Diffuse Long Coronary Artery Disease is Still an Obstacle for Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era?
por: Oh, Pyung Chun, et al.
Publicado: (2019)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Comparison of Optical Coherence Tomographic Assessment between First- and Second-Generation Drug-Eluting Stents
por: Kim, Byeong-Keuk, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fagvhq0d0g47d1t16kscn4ngq2